The EMA will be evaluating nivolumab primarily based on data from the phase II CheckMate-205 trial, which is evaluating nivolumab in both newly diagnosed and previously treated patients with cHL. Results from the study will likely be presented at a scientific meeting later this year, according to Bristol-Myers Squibb (BMS), the developer of the drug. – See more at: http://global.onclive.com/web-exclusives/ema-action-brings-nivolumab-closer-to-first-hematology-approval#sthash.aR1MWGNf.dpuf
Recent Posts
Latest Tweets
-
A final blog for Clive 💜Em x clivevshodgkins.co.uk/blog/it-is-how…
-
Get down and vote tomorrow people mega important. I will be dragging myself down no matter how poorly I feel! https://t.co/C08pUAFVL4
-
So I start my new drug Nivolumab this Friday, I'm one of 1st in country since being approved last Friday. Excited. Apprehensive. Intrigued
-
#WellnessWednesday Forever #AloeBerryNectar is pumped full of goodness. Watch this video to find out how it can ben… twitter.com/i/web/status/8…
-
Back over to hospital today. I shall probably just sleep while they top me up with various. First I need to drag myself outa bed 😞
Leave a Reply